Expert Opinion on Investigational Drugs

Optimal antimicrobial therapy: the balance of potency and exposure
pp. 335-337(3)
Authors: Tillotson, Glenn S; Doern, Gary V; Blondeau, Joseph M

Combating psychosis in Parkinson's disease patients: the use of antipsychotic drugs
pp. 339-349(11)
Authors: Chou, Kelvin L; Fernandez, Hubert H

Targeting the endocannabinoid system in treating brain disorders
pp. 351-365(15)
Authors: Bahr, Ben A; Karanian, David A; Makanji, Sagar S; Makriyannis, Alexandros

Potential therapeutic use of melatonin in migraine and other headache disorders
pp. 367-375(9)
Authors: Peres, Mario FP; Masruha, Marcelo R; Zukerman, Eliova; Moreira-Filho, Carlos Alberto; Cavalheiro, Esper A

Therapeutic potential of the SARMs: revisiting the androgen receptor for drug discovery
pp. 377-387(11)
Authors: Segal, Scott; Narayanan, Ramesh; Dalton, James T

Advances in male hormonal contraception
pp. 389-397(9)
Authors: Meriggiola, Maria Cristina; Pelusi, Giuseppe

Investigational drugs for endometriosis
pp. 399-407(9)
Authors: Chlouber, Richard O; Olive, David L; Pritts, Elizabeth A

Investigational agents for the treatment of growth hormone-insensitivity syndrome
pp. 409-415(7)
Authors: Kemp, Stephen F; Thrailkill, Kathryn M

Oritavancin – an investigational glycopeptide antibiotic
pp. 417-429(13)
Authors: Ward, Kristina E; Mersfelder, Tracey L; LaPlante, Kerry L

Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties
pp. 431-442(12)
Authors: Ahrén, Bo

Tamsulosin and floppy iris syndrome in benign prostatic hyperplasia patients
pp. 443-446(4)
Author: Tiwari, Atul